BMS-955176
BMS-955176 is an experimental second generation HIV maturation inhibitor under development by Bristol-Myers Squibb for use in the treatment of HIV infection. By blocking the maturation of the virus, it prevents viral reproduction in host CD4+ T cells. First generation maturation inhibitors such as bevirimat were ineffective against some naturally occurring changes (polymorphisms) in the Gag protease polyprotein; BMS-955176 has been selected to better tolerate gag polymorphisms.
Wikipage redirect
Link from a Wikipage to another Wikipage
primaryTopic
BMS-955176
BMS-955176 is an experimental second generation HIV maturation inhibitor under development by Bristol-Myers Squibb for use in the treatment of HIV infection. By blocking the maturation of the virus, it prevents viral reproduction in host CD4+ T cells. First generation maturation inhibitors such as bevirimat were ineffective against some naturally occurring changes (polymorphisms) in the Gag protease polyprotein; BMS-955176 has been selected to better tolerate gag polymorphisms.
has abstract
BMS-955176 is an experimental ...... er tolerate gag polymorphisms.
@en
CAS number
1392312-45-6
FDA UNII code
4CA9IAU7RJ
Wikipage page ID
47,310,898
page length (characters) of wiki page
Wikipage revision ID
1,020,535,327
Link from a Wikipage to another Wikipage
CAS number
ChemSpiderID
58,922,159
legal status
Investigational
@en
SMILES
CC[C@@H]1CC[C@]2NCCN7CCSCC7
@en
StdInChIKey
XDMUFNNPLXHNKA-ZTESCHFWSA-N
@en
wikiPageUsesTemplate
hypernym
comment
BMS-955176 is an experimental ...... er tolerate gag polymorphisms.
@en
label
BMS-955176
@en